Trial intelligence / Profile preview

Testosterone patch for low libido in menopausal women

NCT00349791Phase 3Completed

Sponsor
Warner Chilcott
Start
Jun 2002
Primary completion
Oct 2003
Modality
Small Molecules
Countries
3
01

Overview

Phase 3, randomised, double-blind trial of Testosterone TEPI patch in hypoactive sexual desire disorder (HSDD) (2 arms), sponsored by Warner Chilcott. Primary endpoint: Change from baseline in the frequency of total satisfying sexual activity captured by the Sexual Activity Log (SAL) at 2 years. Started Jun 2002; status: completed.

02

Drugs

Testosterone TEPI patch
03

Conditions

hypoactive sexual desire disorder (HSDD)

Beyond the preview

Go deeper on NCT00349791.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00349791.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call